Publication
The roadmap of RANKL/RANK pathway in cancer
| dc.contributor.author | Casimiro, Sandra | |
| dc.contributor.author | Vilhais, Guilherme | |
| dc.contributor.author | Fernandes Gomes, Inês | |
| dc.contributor.author | Costa, Luis | |
| dc.date.accessioned | 2022-09-23T12:46:13Z | |
| dc.date.available | 2022-09-23T12:46:13Z | |
| dc.date.issued | 2021 | |
| dc.description | © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). | pt_PT |
| dc.description.abstract | The receptor activator of the nuclear factor-κB ligand (RANKL)/RANK signaling pathway was identified in the late 1990s and is the key mediator of bone remodeling. Targeting RANKL with the antibody denosumab is part of the standard of care for bone loss diseases, including bone metastases (BM). Over the last decade, evidence has implicated RANKL/RANK pathway in hormone and HER2-driven breast carcinogenesis and in the acquisition of molecular and phenotypic traits associated with breast cancer (BCa) aggressiveness and poor prognosis. This marked a new era in the research of the therapeutic use of RANKL inhibition in BCa. RANKL/RANK pathway is also an important immune mediator, with anti-RANKL therapy recently linked to improved response to immunotherapy in melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). This review summarizes and discusses the pre-clinical and clinical evidence of the relevance of the RANKL/RANK pathway in cancer biology and therapeutics, focusing on bone metastatic disease, BCa onset and progression, and immune modulation. | pt_PT |
| dc.description.sponsorship | This work was supported by the research project PTDC/MED-ONC/28636/2017 from Fundação para a Ciência e a Tecnologia (FCT)/Ministério da Ciência, Tecnologia e Ensino Superior (MCTES) through Fundos do Orçamento de Estado. IG is supported by the FCT PhD grant SFRH/BD/139178/2018. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | Cells. 2021 Aug 4;10(8):1978 | pt_PT |
| dc.identifier.doi | 10.3390/cells10081978 | pt_PT |
| dc.identifier.eissn | 2073-4409 | |
| dc.identifier.uri | http://hdl.handle.net/10451/54559 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.publisher | MDPI | pt_PT |
| dc.relation | Physiopathology and clinical implications of the RANK c.1386C>T (R450W) mutation in breast cancer patients | |
| dc.relation | RANK-pathway as a mediator of resistance to cyclin inhibitors and HER2-targeted therapies in breast cancer | |
| dc.relation.publisherversion | https://www.mdpi.com/journal/cells | pt_PT |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt_PT |
| dc.subject | RANK ligand (RANKL) | pt_PT |
| dc.subject | Bone metastasis | pt_PT |
| dc.subject | Bone-targeted agent | pt_PT |
| dc.subject | Breast cancer | pt_PT |
| dc.subject | Drug repurposing | pt_PT |
| dc.subject | Receptor activator of nuclear factor-κB (RANK) | pt_PT |
| dc.subject | Targeted therapy | pt_PT |
| dc.title | The roadmap of RANKL/RANK pathway in cancer | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.awardTitle | Physiopathology and clinical implications of the RANK c.1386C>T (R450W) mutation in breast cancer patients | |
| oaire.awardTitle | RANK-pathway as a mediator of resistance to cyclin inhibitors and HER2-targeted therapies in breast cancer | |
| oaire.awardURI | info:eu-repo/grantAgreement/FCT/3599-PPCDT/PTDC%2FMED-ONC%2F28636%2F2017/PT | |
| oaire.awardURI | info:eu-repo/grantAgreement/FCT//SFRH%2FBD%2F139178%2F2018/PT | |
| oaire.citation.issue | 8 | pt_PT |
| oaire.citation.title | Cells | pt_PT |
| oaire.citation.volume | 10 | pt_PT |
| oaire.fundingStream | 3599-PPCDT | |
| person.familyName | Cara de Anjo Casimiro | |
| person.familyName | Fernandes Gomes | |
| person.familyName | Costa | |
| person.givenName | Sandra Cristina | |
| person.givenName | Inês | |
| person.givenName | Luis | |
| person.identifier.ciencia-id | 0F12-5181-0B22 | |
| person.identifier.ciencia-id | 4114-34EA-AD95 | |
| person.identifier.ciencia-id | 041E-4ADE-FB64 | |
| person.identifier.orcid | 0000-0002-6917-4477 | |
| person.identifier.orcid | 0000-0003-0985-0821 | |
| person.identifier.orcid | 0000-0002-4782-7318 | |
| person.identifier.scopus-author-id | 14043403400 | |
| project.funder.identifier | http://doi.org/10.13039/501100001871 | |
| project.funder.identifier | http://doi.org/10.13039/501100001871 | |
| project.funder.name | Fundação para a Ciência e a Tecnologia | |
| project.funder.name | Fundação para a Ciência e a Tecnologia | |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |
| relation.isAuthorOfPublication | fd665de1-a7e6-4638-94c3-ecc645f84607 | |
| relation.isAuthorOfPublication | 730a372f-c20e-4327-a9a1-f84ea7dff0bb | |
| relation.isAuthorOfPublication | 8a2ab4c6-ba86-4433-b4b7-6256d81890e5 | |
| relation.isAuthorOfPublication.latestForDiscovery | 8a2ab4c6-ba86-4433-b4b7-6256d81890e5 | |
| relation.isProjectOfPublication | c94dfe35-50fb-443d-8aae-d8207d0da300 | |
| relation.isProjectOfPublication | 93611b64-0e0d-48b0-8c45-920f7c845b48 | |
| relation.isProjectOfPublication.latestForDiscovery | c94dfe35-50fb-443d-8aae-d8207d0da300 |